Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 195

1.

Necrotizing Granulomas in a Patient With Psoriasis and Sarcoidosis After Adalimumab-Medication-Induced Reaction or Reactivation of Latent Disease?

Turkowski Y, Konnikov N, Mahalingam M.

Am J Dermatopathol. 2019 Feb 28. doi: 10.1097/DAD.0000000000001394. [Epub ahead of print]

PMID:
30839343
2.

A sequestered fusion peptide in the structure of an HIV-1 transmitted founder envelope trimer.

Ananthaswamy N, Fang Q, AlSalmi W, Jain S, Chen Z, Klose T, Sun Y, Liu Y, Mahalingam M, Chand S, Tovanabutra S, Robb ML, Rossmann MG, Rao VB.

Nat Commun. 2019 Feb 20;10(1):873. doi: 10.1038/s41467-019-08825-7.

3.

Nucleotide-dependent DNA gripping and an end-clamp mechanism regulate the bacteriophage T4 viral packaging motor.

Ordyan M, Alam I, Mahalingam M, Rao VB, Smith DE.

Nat Commun. 2018 Dec 21;9(1):5434. doi: 10.1038/s41467-018-07834-2.

4.

Demographics, Risk Factors, and Incidence of Melanoma in Patients in the New England VA Healthcare system.

Bae E, Leone D, Konnikov N, Mahalingam M.

Mil Med. 2018 Nov 5. doi: 10.1093/milmed/usy267. [Epub ahead of print]

PMID:
30395278
5.

A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague.

Tao P, Mahalingam M, Zhu J, Moayeri M, Sha J, Lawrence WS, Leppla SH, Chopra AK, Rao VB.

MBio. 2018 Oct 16;9(5). pii: e01926-18. doi: 10.1128/mBio.01926-18.

6.

Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.

Yang S, Leone DA, Biswas A, Deng A, Jukic D, Singh R, Sundram U, Mahalingam M.

Hum Pathol. 2018 Dec;82:206-214. doi: 10.1016/j.humpath.2018.08.002. Epub 2018 Aug 16.

PMID:
30120967
7.

Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases.

Tao P, Zhu J, Mahalingam M, Batra H, Rao VB.

Adv Drug Deliv Rev. 2018 Jul 6. pii: S0169-409X(18)30164-9. doi: 10.1016/j.addr.2018.06.025. [Epub ahead of print] Review.

PMID:
29981801
8.

Laser Capture Microdissection: Insights into Methods and Applications.

Mahalingam M.

Methods Mol Biol. 2018;1723:1-17. doi: 10.1007/978-1-4939-7558-7_1.

PMID:
29344852
9.

Cutaneous Rosai-Dorfman Disease With Linear Lesions and Monoclonal Gammopathy.

Bae E, White P, Brophy M, Lichtman M, Krathen MS, Mahalingam M.

Am J Dermatopathol. 2017 Oct;39(10):776-781. doi: 10.1097/DAD.0000000000000875.

PMID:
28930107
10.

A Bivalent Anthrax-Plague Vaccine That Can Protect against Two Tier-1 Bioterror Pathogens, Bacillus anthracis and Yersinia pestis.

Tao P, Mahalingam M, Zhu J, Moayeri M, Kirtley ML, Fitts EC, Andersson JA, Lawrence WS, Leppla SH, Chopra AK, Rao VB.

Front Immunol. 2017 Jun 26;8:687. doi: 10.3389/fimmu.2017.00687. eCollection 2017.

11.

PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies.

Frydenlund N, Mahalingam M.

Hum Pathol. 2017 Aug;66:13-33. doi: 10.1016/j.humpath.2017.06.012. Epub 2017 Jul 8. Review.

PMID:
28694003
12.

Frailty Syndrome and Risk of Sepsis in the REasons for Geographic And Racial Differences in Stroke (REGARDS) Cohort.

Mahalingam M, Moore JX, Donnelly JP, Safford MM, Wang HE.

J Intensive Care Med. 2019 Apr;34(4):292-300. doi: 10.1177/0885066617715251. Epub 2017 Jul 5.

13.

An Annular Plaque on the Inner Thigh.

Chung HJ, Kafle SU, Lam C, Mahalingam M.

Am J Dermatopathol. 2017 Jul;39(7):e85. doi: 10.1097/DAD.0000000000000520. No abstract available.

PMID:
28632574
14.

Annular Plaque on the Inner Thigh.

Chung HJ, Kafle SU, Lam C, Mahalingam M.

Am J Dermatopathol. 2017 Jul;39(7):551-552. doi: 10.1097/DAD.0000000000000521. No abstract available.

PMID:
28632570
15.

Glycosylation and oligomeric state of envelope protein might influence HIV-1 virion capture by α4β7 integrin.

Chand S, Messina EL, AlSalmi W, Ananthaswamy N, Gao G, Uritskiy G, Padilla-Sanchez V, Mahalingam M, Peachman KK, Robb ML, Rao M, Rao VB.

Virology. 2017 Aug;508:199-212. doi: 10.1016/j.virol.2017.05.016. Epub 2017 May 31.

16.

Lack of specificity of cytokeratin-15 loss in scarring alopecias.

Mahalingam M.

J Am Acad Dermatol. 2017 Apr;76(4):e135-e136. doi: 10.1016/j.jaad.2016.11.066. No abstract available.

PMID:
28325418
17.

MSH6, Past and Present and Muir-Torre Syndrome-Connecting the Dots.

Mahalingam M.

Am J Dermatopathol. 2017 Apr;39(4):239-249. doi: 10.1097/DAD.0000000000000633. Review.

PMID:
28323777
18.

Neurotrophin Receptors and Perineural Invasion: Analyses in Select Lineage-Unrelated Cutaneous Malignancies With a Propensity for Perineural Invasion.

Frydenlund NF, Mahalingam M.

Vitam Horm. 2017;104:497-531. doi: 10.1016/bs.vh.2016.11.003. Epub 2016 Dec 13. Review.

PMID:
28215306
19.

Tumoral PD-L1 expression in desmoplastic melanoma is associated with depth of invasion, tumor-infiltrating CD8 cytotoxic lymphocytes and the mixed cytomorphological variant.

Frydenlund N, Leone D, Yang S, Hoang MP, Deng A, Hernandez-Perez M, Singh R, Biswas A, Yaar R, Mahalingam M.

Mod Pathol. 2017 Mar;30(3):357-369. doi: 10.1038/modpathol.2016.210. Epub 2017 Jan 13.

20.

NF1 and Neurofibromin: Emerging Players in the Genetic Landscape of Desmoplastic Melanoma.

Mahalingam M.

Adv Anat Pathol. 2017 Jan;24(1):1-14. Review.

PMID:
27941538
21.

BRAF and epithelial-mesenchymal transition in papillary thyroid carcinoma - challenging the roles of Snail and E-Cadherin?

Mitchell B, Leone D, Yang S, Khan A, Mahalingam M, Dhingra J.

Am J Transl Res. 2016 Nov 15;8(11):5076-5086. eCollection 2016.

22.

Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): A clinicopathologic analysis of predictors of outcome.

Lawrence NF, Hammond MR, Frederick DT, Su Y, Dias-Santagata D, Deng A, Selim MA, Mahalingam M, Flaherty KT, Hoang MP.

J Am Acad Dermatol. 2016 Sep;75(3):595-602. doi: 10.1016/j.jaad.2016.04.059.

PMID:
27543214
23.

Hemostasis biomarkers and risk of sepsis: the REGARDS cohort.

Moore JX, Zakai NA, Mahalingam M, Griffin RL, Irvin MR, Safford MM, Baddley JW, Wang HE.

J Thromb Haemost. 2016 Nov;14(11):2169-2176. doi: 10.1111/jth.13446. Epub 2016 Sep 23.

24.

Frequency of telomerase reverse transcripter promoter mutations in desmoplastic melanoma subtypes: analyses of 76 cases.

Yang S, Leone D, Frydenlund N, Hoang M, Deng A, Hernandez-Perez M, Biswas A, Singh R, Yaar R, Mahalingam M.

Melanoma Res. 2016 Aug;26(4):361-6. doi: 10.1097/CMR.0000000000000272.

PMID:
27244099
25.

BRAF and Epithelial-Mesenchymal Transition: Lessons From Papillary Thyroid Carcinoma and Primary Cutaneous Melanoma.

Mitchell B, Dhingra JK, Mahalingam M.

Adv Anat Pathol. 2016 Jul;23(4):244-71. doi: 10.1097/PAP.0000000000000113. Review.

PMID:
27145091
26.
27.

Highly Effective Soluble and Bacteriophage T4 Nanoparticle Plague Vaccines Against Yersinia pestis.

Tao P, Mahalingam M, Rao VB.

Methods Mol Biol. 2016;1403:499-518. doi: 10.1007/978-1-4939-3387-7_28.

28.

Neurofibromin protein loss in desmoplastic melanoma subtypes: implicating NF1 allelic loss as a distinct genetic driver?

Kadokura A, Frydenlund N, Leone DA, Yang S, Hoang MP, Deng A, Hernandez-Perez M, Biswas A, Singh R, Yaar R, Mahalingam M.

Hum Pathol. 2016 Jul;53:82-90. doi: 10.1016/j.humpath.2016.02.012. Epub 2016 Mar 9.

PMID:
26980030
29.

BRAF and epithelial-mesenchymal transition in primary cutaneous melanoma: a role for Snail and E-cadherin?

Mitchell B, Leone DA, Feller JK, Yang S, Mahalingam M.

Hum Pathol. 2016 Jun;52:19-27. doi: 10.1016/j.humpath.2015.12.030. Epub 2016 Feb 1.

PMID:
26980024
30.

Zoledronic Acid-Induced Interface Dermatitis.

Succaria F, Collier M, Mahalingam M.

Am J Dermatopathol. 2015 Dec;37(12):933-5. doi: 10.1097/DAD.0000000000000341.

31.

Mycosis Fungoides, Then and Now… Have We Travelled?

Mahalingam M, Reddy VB.

Adv Anat Pathol. 2015 Nov;22(6):376-83. doi: 10.1097/PAP.0000000000000092. Review.

PMID:
26452212
32.

The HGF-cMET signaling pathway in conferring stromal-induced BRAF-inhibitor resistance in melanoma.

Filitis DC, Rauh J, Mahalingam M.

Melanoma Res. 2015 Dec;25(6):470-8. doi: 10.1097/CMR.0000000000000194. Review.

PMID:
26317169
33.

Fabrication and optimization of camptothecin loaded Eudragit S 100 nanoparticles by Taguchi L4 orthogonal array design.

Mahalingam M, Krishnamoorthy K.

Int J Pharm Investig. 2015 Jul-Sep;5(3):147-54. doi: 10.4103/2230-973X.160852.

34.

Dark Brown Plaques and Patches on the Breast and Areola in a 14-Year-Old Female. Nevoid hyperkeratosis of the areola and breast.

Succaria F, Rosenbaum M, Goldberg LJ, Mahalingam M.

Am J Dermatopathol. 2015 Aug;37(8):621-2, 659. doi: 10.1097/DAD.0000000000000181. No abstract available.

PMID:
26193708
35.

A New Approach to Produce HIV-1 Envelope Trimers: BOTH CLEAVAGE AND PROPER GLYCOSYLATION ARE ESSENTIAL TO GENERATE AUTHENTIC TRIMERS.

AlSalmi W, Mahalingam M, Ananthaswamy N, Hamlin C, Flores D, Gao G, Rao VB.

J Biol Chem. 2015 Aug 7;290(32):19780-95. doi: 10.1074/jbc.M115.656611. Epub 2015 Jun 18.

36.

Perineural invasion in cutaneous squamous cell carcinoma: role of immunohistochemistry, anatomical site, and the high-affinity nerve growth factor receptor TrkA.

Frydenlund N, Leone DA, Mitchell B, Abbas O, Dhingra J, Mahalingam M.

Hum Pathol. 2015 Aug;46(8):1209-16. doi: 10.1016/j.humpath.2015.05.003. Epub 2015 May 22.

PMID:
26072357
37.

A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI.

Rath PC, Chidambaram S, Rath P, Dikshit B, Naik S, Sahoo PK, Das B, Mahalingam M, Khandrika L, Jain J.

Indian Heart J. 2015 Mar-Apr;67(2):114-21. doi: 10.1016/j.ihj.2015.03.017. Epub 2015 Apr 27.

38.

Desmoplastic melanoma, neurotropism, and neurotrophin receptors--what we know and what we do not.

Frydenlund N, Mahalingam M.

Adv Anat Pathol. 2015 Jul;22(4):227-41. doi: 10.1097/PAP.0000000000000076. Review.

PMID:
26050260
39.

Methods for labeling skeletal muscle ion channels site-specifically with fluorophores suitable for FRET-based structural analysis.

Mahalingam M, Fessenden JD.

Methods Enzymol. 2015;556:455-74. doi: 10.1016/bs.mie.2014.11.049. Epub 2015 Mar 20.

PMID:
25857795
40.

Painless penile papule.

Marszalek RM, Bae-Harboe YS, Mahalingam M, Masterpol K.

J Fam Pract. 2015 Mar;64(3):185-8. No abstract available.

PMID:
25789346
41.

Selection of a suitable method for the preparation of polymeric nanoparticles: multi-criteria decision making approach.

Krishnamoorthy K, Mahalingam M.

Adv Pharm Bull. 2015 Mar;5(1):57-67. doi: 10.5681/apb.2015.008. Epub 2015 Mar 5.

42.

Neurotrophin receptors and perineural invasion in desmoplastic melanoma.

Frydenlund N, Leone DA, Mitchell B, Yang S, Deng A, Hoang MP, Mahalingam M.

J Am Acad Dermatol. 2015 May;72(5):851-8. doi: 10.1016/j.jaad.2015.01.026. Epub 2015 Mar 7.

PMID:
25752716
43.

Mutation stability in primary and metastatic melanoma: what we know and what we don't.

Varada S, Mahalingam M.

Histol Histopathol. 2015 Jul;30(7):763-70. doi: 10.14670/HH-11-584. Epub 2015 Jan 13. Review.

PMID:
25585249
44.

Cutaneous Myopericytoma: A Report of 3 Cases and Review of the Literature.

Aung PP, Goldberg LJ, Mahalingam M, Bhawan J.

Dermatopathology (Basel). 2015 Feb 11;2(1):9-14. doi: 10.1159/000371875. eCollection 2015 Jan-Mar.

45.

Microvessel density, lymphovascular density, and lymphovascular invasion in primary cutaneous melanoma-correlation with histopathologic prognosticators and BRAF status.

Aung PP, Leone D, Feller JK, Yang S, Hernandez M, Yaar R, Singh R, Helm T, Mahalingam M.

Hum Pathol. 2015 Feb;46(2):304-12. doi: 10.1016/j.humpath.2014.11.006. Epub 2014 Nov 26.

PMID:
25537974
46.

Reading between the layers: early histopathological findings in exogenous ochronosis.

Chowdary S, Mahalingam M, Vashi NA.

Am J Dermatopathol. 2014 Dec;36(12):989-91. doi: 10.1097/DAD.0000000000000142.

PMID:
25415140
47.

Erythema nodosum of non-lower-extremity sites: a histopathologic reappraisal.

Perez-Chua T, Miller DD, Mahalingam M.

G Ital Dermatol Venereol. 2016 Dec;151(6):710-713. Epub 2014 Nov 19. No abstract available.

PMID:
25407105
48.

Pseudoxanthoma elasticum-like change adjacent to a benign adnexal neoplasm: a histopathologic reaction pattern.

Aung PP, Mahalingam M.

Am J Dermatopathol. 2015 Feb;37(2):157-9. doi: 10.1097/DAD.0000000000000215.

PMID:
25365498
49.

Correlation of chemokine receptor CXCR4 mRNA in primary cutaneous melanoma with established histopathologic prognosticators and the BRAF status.

Mitchell B, Leone D, Feller JK, Bondzie P, Yang S, Park HY, Mahalingam M.

Melanoma Res. 2014 Dec;24(6):621-5. doi: 10.1097/CMR.0000000000000120.

PMID:
25211166
50.

Structural mapping of divergent regions in the type 1 ryanodine receptor using fluorescence resonance energy transfer.

Mahalingam M, Girgenrath T, Svensson B, Thomas DD, Cornea RL, Fessenden JD.

Structure. 2014 Sep 2;22(9):1322-1332. doi: 10.1016/j.str.2014.07.003. Epub 2014 Aug 14.

Supplemental Content

Loading ...
Support Center